ASP Isotopes (ASPI) Projected to Post Earnings on Friday

ASP Isotopes (NASDAQ:ASPI) is expected to be announcing its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $4.4660 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.The business had revenue of $8.36 million during the quarter, compared to analysts’ expectations of $3.68 million.

ASP Isotopes Trading Down 0.5%

NASDAQ ASPI opened at $4.30 on Thursday. ASP Isotopes has a 12 month low of $3.51 and a 12 month high of $14.49. The stock has a market cap of $659.23 million, a P/E ratio of -2.07 and a beta of 3.61. The stock’s fifty day moving average price is $5.30 and its 200-day moving average price is $5.47. The company has a current ratio of 4.39, a quick ratio of 4.37 and a debt-to-equity ratio of 0.69.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.00.

Insider Transactions at ASP Isotopes

In related news, CFO Heather Kiessling sold 23,124 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $6.28, for a total transaction of $145,218.72. Following the transaction, the chief financial officer owned 1,526,252 shares in the company, valued at $9,584,862.56. This represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Todd Wider sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $6.25, for a total transaction of $312,500.00. Following the completion of the sale, the director owned 722,247 shares in the company, valued at $4,514,043.75. This represents a 6.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 279,079 shares of company stock valued at $2,049,208. Company insiders own 14.40% of the company’s stock.

Hedge Funds Weigh In On ASP Isotopes

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in shares of ASP Isotopes in the third quarter worth $34,000. BNP Paribas Financial Markets increased its position in ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after acquiring an additional 2,548 shares during the last quarter. Legal & General Group Plc lifted its holdings in ASP Isotopes by 30.4% in the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after acquiring an additional 1,953 shares during the period. Tower Research Capital LLC TRC lifted its holdings in ASP Isotopes by 96.7% in the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock valued at $80,000 after acquiring an additional 5,353 shares during the period. Finally, Guggenheim Capital LLC purchased a new position in ASP Isotopes in the fourth quarter worth about $72,000. 16.80% of the stock is owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.